VJHemOnc Podcast Novel CD20/CD3 bispecific antibodies in NHL
Aug 17, 2021
Promising results in non-Hodgkin lymphoma treatment using bispecific antibodies, including CD20/CD3. These antibodies have shown encouraging response rates in aggressive and indolent NHL. Case studies highlight complete remission and use as a bridge to CAR T-cell therapy or retreatment. Glofit MAB, a two-to-one format bispecific antibody with high binding affinity to CD20, shows promising response rates. Testing step dosing regimen improves safety and efficacy of CD20/CD3 bispecific antibodies. ODRIN-XDIMAP Phase 1 study reveals potential biomarker associations.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 3min
Effectiveness and Durability of Novel CD20/CD3 Bispecific Antibodies in NHL
03:02 • 4min
Overview of Glofit MAB: A Novel CD20/CD3 Bispecific Antibody in Lymphoma Landscape
06:55 • 6min
Testing Step Dosing Regimen for CD20/CD3 Bispecific Antibodies
12:25 • 9min
Findings of ODRIN-XDIMAP Phase 1 Study and Potential Biomarker Associations
21:36 • 3min